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Abstract
Chemotherapy aims to limit proliferation and induce apoptotic cell death in tumor cells. Owing to blockade of sig-
naling pathways involved in cell survival and proliferation, nuclear factor κB (NF-κB) inhibitors can induce apoptosis in
a number of hematological malignancies. The efficacy of conventional chemotherapeutic drugs, such as vincristine
(VCR) and doxorubicine (DOX), may be enhanced with combined therapy based on NF-κB modulation. In this study,
we evaluated the effect of caffeic acid phenylethyl ester (CAPE) and MG-132, two nonspecific NF-κB inhibitors,
and conventional chemotherapeutics drugs DOX and VCR on cell proliferation and apoptosis induction on a lympho-
blastoid B-cell line, PL104, established and characterized in our laboratory. CAPE and MG-132 treatment showed a
strong antiproliferative effect accompanied by clear cell cycle deregulation and apoptosis induction. Doxorubicine
and VCR showed antiproliferative effects similar to those of CAPE and MG-132, although the latter drugs showed
an apoptotic rate two-fold higher than DOX and VCR. None of the four compounds showed cytotoxic effect on
peripheral mononuclear cells from healthy volunteers. CAPE- and MG-132–treated bone marrow cells from patients
with myeloid and lymphoid leukemias showed 69% (P < .001) and 25% decrease (P < .01) in cell proliferation and
42% and 34% (P < .01) apoptosis induction, respectively. Overall, our results indicate that CAPE and MG-132 had a
strong and selective apoptotic effect on tumor cells that may be useful in future treatment of hematological neoplasias.
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Introduction
Cancer is a multifactorial disease that generally requires multimodal ther-
apy owing to the complexity and diversity of factors that control its pro-
gression and dissemination. The accepted modality of treatment may
involve surgery, radiation, and drugs, singly or in combination. Chemo-
therapeutic agents can often provide temporary relief from symptoms,
prolongation of life span, and occasionally, a complete cure. How-
ever, drug and radiation treatments have two major problems, namely,
a time-dependent development of tumor resistance to therapy and a
nonspecific toxicity toward normal cells, which are in part responsible
for the impediment to achieve an effective cancer treatment [1].
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Previous data have shown that apoptosis, the most common and
well-defined form of programmed cell death, is the main cause of
tumor cell death after radiotherapy and chemotherapy treatment of
hematological malignancies, representing an efficient strategy for can-
cer chemotherapy [2]. However, abnormal control of cell death path-
ways has also been related to treatment failure, which may in turn lead
to multidrug resistance (MDR) emergence [3]. Despite this, apoptosis
induction may be considered a reliable marker for the evaluation of
potential anticancer agents [4], and its modulation may be a useful
weapon in the oncologist’s armamentarium for the design and manage-
ment of suitable therapeutic protocols for tumor malignancies.
Nuclear factor κB (NF-κB) is a transcription factor that operates in
virtually all mammalian cells [5]. Because NF-κB regulates the expres-
sion of a wide variety of proteins that inhibit apoptosis and promote cell
survival and proliferation, it is strongly implicated in the promotion,
progression, and metastasis [6,7] of solid cancers [8], sarcomas [9],
and several hematological malignancies, as well as acute and chronic
myeloid leukemias [10], lymphoblastic leukemias [11], myelodysplastic
syndrome [12], multiple myeloma [13], and lymphomas [14]. The
antiapoptotic role of the NF-κB cascade has made it an attractive target
for the development of specific anticancer drugs [15]. Over the years,
several conventional drugs have shown to be effective anti–NF-κB com-
pounds. Some of these agents are currently used in cancer therapy,
whereas others are being tested in clinical trials [16,17]. Agents that
inhibit the 26S proteasome physiological function [18], such as peptide
aldehydes (MG-132, ALLN), may indirectly interfere with NF-κB
pathway [19]. Many dietary agents of vegetable origin have shown to
inhibit NF-κB and induce apoptosis of tumor cells [20,21]. Caffeic
acid phenylethyl ester (CAPE), a biologically active polyphenolic com-
pound of propolis from honeybee hives, has demonstrated to be a
potent inhibitor of NF-κB activation [20]. In addition, CAPE has sev-
eral interesting biological properties including antioxidant [22], anti-
inflammatory [23], antiviral [24], antibacterial [25], antifungal [26],
immunostimulatory, antiangiogenic, anti-invasive, antitumoral, and anti-
metastatic activities [27].
The aim of this study was to assess the potential usefulness of two
nonspecific NF-κB inhibitors, CAPE and MG-132, as chemotherapeu-
tic agents or chemosensitizers of tumor cells in the treatment of hemato-
logical malignancies.
Our results showed that CAPE and MG-132 exerted a potent and
highly selective cytotoxic effect mediated by apoptosis induction, cell
cycle deregulation, and reduction of the proliferation rate on a novel
lymphoblastoid B-cell line as well as on primary human leukemic
cells. The combined treatment with CAPE or MG-132 plus conven-
tional chemotherapeutic agents showed an increase in apoptotic cell
death, which deserves further studies.
Materials and Methods
Materials
CAPE and MG-132 were obtained from Calbiochem (San Diego,
CA), and stock solutions were prepared in dimethylsulfoxide (DMSO)
at 350 and 5 mM stock concentration, respectively. Vincristine (VCR)
was kindly provided by Filaxis Pharmaceuticals (Buenos Aires, Argen-
tina) and doxorubicine (DOX) by Gador Pharmaceuticals (Buenos
Aires, Pharmaceuticals). RPMI-1640, penicillin, and streptomycin
reagents were purchased from Invitrogen (Buenos Aires, Argentina).
Antibodies against p65, IκB-α, p-IκB-α, actin, horseradish peroxidase–
labeled antirabbit, antimouse, antigoat secondary antibodies andWestern
blot analysis chemiluminiscence reagent were bought from Santa Cruz
Biotechnology, Inc. (Buenos Aires, Argentina).
Cell Lines and Culture Conditions
The cell line PL104 was established in our laboratory from bone
marrow aspirate from a 14-year-old patient with an atypical acute
myeloid leukemia according to the French-American-British classifica-
tion. A written informed consent was previously obtained from the
patient in accordance with the Declaration of Helsinki. After Ficoll-
Hypaque (Sigma-Aldrich, St. Louis, MO) density gradient separa-
tion, cells were recovered and grown in a suspension culture at 37°C
in a 5% CO2 atmosphere using RPMI-1640 medium supplemented
with 15% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine,
20 mM HEPES buffer, 100 mg/ml penicillin, 150 mg/ml strepto-
mycin, and 50 mM 2-mercaptoethanol. Cells were subcultured at 1:2
to 1:4 ratios every 2 to 3 days with a viability greater than 90% (assessed
by trypan blue) and finally showed definite proliferation in vitro after
30 passages. The established cell line grew in suspension culture either
as single units or as loose clumps with a doubling time of 25.09 ±
4.41 hours, as determined by the MTS assay. Aliquots of the cells were
frozen in liquid nitrogen, and thawed cells proliferated under standard
culture conditions.
Collection and Processing of Primary Cells
Patient-derived leukemic (PDL) cells were obtained, previous in-
formed consent, from bone marrow aspirates in sterile syringes con-
taining EDTA as anticoagulant. Samples from 20 nontreated patients
at diagnosis, immunophenotypically characterized as acute myeloid
leukemia [8], acute lymphoblastic leukemia [7], chronic lympho-
blastic leukemia [3], and chronic myeloid leukemia [2], were analyzed.
The group of patients comprised 16 males and 4 females, and the mean
age at presentation was 61.6 ± 23.1 years (range, 3-63 years). Patients
who were under treatment or relapse phase were excluded. Normal
peripheral blood samples were obtained after informed consent from
10 healthy volunteers. The male-to-female ratio was 5:5 with a mean
age of 35 years (range, 23-60 years). Accordingly, bonemarrow or blood
cells were subjected to Ficoll-Hypaque density gradient separation to
isolate leukemic cells or peripheral blood mononuclear cells (PBMCs).
In both cases, primary cells were cultured in RPMI-1640 containing
20% FCS at 37°C in a humidified atmosphere with 5% CO2. Cell
viability was greater than 95%, as assessed by trypan blue exclusion.
These studies have been approved by The Scientific Review Board of
FUNDALEU (Buenos Aires, Argentina) and were in accordance with
the Declaration of Helsinki.
Immunophenotyping
Three-color immunofluorescence analysis of surface and intracellular
antigens was performed by using combinations of phycoerythrin, fluo-
rescein isothiocyanate (FITC), and/or peridinin chlorophyll protein–
conjugated monoclonal antibodies (MoAbs), as previously described
[28]. The following MoAbs were used: CD3, CD19, CD34, CD45
(peridinin chlorophyll protein); CD8, CD10, CD15, CD16, CD20,
CD41a, CD64, HLADR, myeloperoxidase (MPO), kappa chain
(FITC); CD4, CD11b, CD13, CD14, CD22, CD33, CD38, CD56,
CD79a, CD117, and lambda chain (phycoerythrin), all purchased
from BD Biosciences (BD PharMingen, San Diego, CA). Analysis was
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carried out on a FACScan Becton Dickinson (Los Angeles, CA) flow
cytometer using Cell Quest (Becton Dickinson Immunocytometry
Systems) software. Staining patterns for all antibodies used were com-
pared with their respective isotype control. Positive results were expressed
as a percentage with cutoff values of 20% over the corresponding iso-
typic control.
Cell Clot Block Preparation
Cells (2 × 107/ml) from a cell culture suspension were spun down at
900g, and the supernatant was finally discarded. Two volumes of a
90% ethanol/40% formalin/acetic acid (80:15:5) solution were added
and gently mixed by inversion. After 24 hours, the clot was pulled out
onto a filter paper, and slides were prepared for histologic analysis.
Detection of Epstein-Barr Virus Antigens
by Immunohistochemistry
Formalin-fixed paraffin-embedded sections of a cell clot block were
assayed for EBNA1 (clone 1H4) and LMP2A (clone 4E11) expression
with MoAbs kindly provided by Dr. E. Kremmer (Forschungszentrum
für Umwelt und Gesundheit GmbH, Institut für Immulogie, Munchen,
Germany). Antigen unmasking was carried out in 0.01 M sodium cit-
rate (pH 6) for 5 minutes at 500 W in a microwave oven. Immuno-
histochemical detection of MoAbs was performed using an antirat
polyclonal antibody peroxidase-conjugated. Slides were stained in
freshly prepared substrate solution (10 mg of diaminobenzidine in
15 ml of Tris-buffered saline, 30 μl of H2O2, pH 7.6). Hematoxylin
counterstaining was applied. As negative controls, the pertinent anti-
bodies were omitted. As a positive control, a well-characterized Epstein-
Barr virus (EBV)–positive Hodgkin lymphoma biopsy was used.
Polymerase Chain Reaction Amplification
To confirm EBV presence, a polymerase chain reaction (PCR) was
carried out to amplify a 122-bp fragment of EBV DNA sequence
encoding BamH1W (IR1) as described by Saito et al. [29]. In a sepa-
rate reaction tube, a PCR was carried out to amplify a beta-globin
gene as a control to monitor the amplification ability of a single-copy
gene. Amplified DNA was subjected to electrophoresis on a 2% aga-
rose gel with ethidium bromide (EtBr).
Epstein-Barr Encoded RNA In Situ Hybridization
Epstein-Barr Encoded RNA in situ hybridization was performed on
paraffin sections according to the manufacturer’s instructions using
an EBV Probe ISH Kit, NCL-EBV-K (Novocastra Laboratories, Ltd,
Newcastle, United Kingdom).
Cell Growth Inhibition Assay
Sensitivity of the cell line to increased doses of DOX (0-2 μM),
VCR (0-10 μM), CAPE (0-100 μg/ml), or MG-132 (0-4 μM) was
determined by culturing 5 × 105 cells/ml at 37°C in a 5% CO2 atmo-
sphere for 24 and 48 hours, pulsed with 1 μCi [3H]TdR (DuPont,
Nen Products, Boston, MA) for the last 18 hours and harvested as
described previously [30]. Cells were counted in a liquid scintillation
beta counter (Beckman, MD). Results were calculated from the mean
counts per minute of [3H]TdR incorporated in triplicate cultures. Per-
centage of cell proliferation inhibition for each treatment was calcu-
lated as follows:
%Cell survival ¼ ½ðcpm cells plus drug treatment=
cpm cells aloneÞ 100
%Cell prolif eration inhibition ¼ 100 − % cell survival
Each experiment was performed at least three times. Nontreated cells
represented 100% cell survival. Cell viability at the beginning of the
experiment was higher than 95%, as assessed by trypan blue exclusion.
Preparation of Nuclear and Cytoplasmic Extracts
Nuclear extracts were prepared as previously described [31]. Briefly,
cells were incubated in 400 μl of hypotonic buffer (10 mM HEPES
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM
PMSF, 0.1% Nonidet P-40) for 15 minutes on ice and centrifuged
at 11,000g for 10 minutes. Nuclear pellets were resuspended in 60 μl
of nuclear hypotonic buffer (20 mM HEPES, 1.5 mM MgCl2,
420 mM NaCl, 0.5 mM DTT, 0.5 mM PMSF, 0.2 mM EDTA,
25% glycerol) and incubated at 4°C for 15 minutes followed by cen-
trifugation at 13,000g for 15 minutes.
For cytoplasmic extracts preparation, cells were lysed with a hypo-
tonic buffer (20 mM Tris pH 8.0, 150 mMNaCl, 100 mMNaF, 10%
glycerol, 1% Nonidet P-40, 1 mM PMSF, 40 μg/ml leupeptin, and
20 μg/ml aprotinin) for 30 minutes at 4°C.
The supernatants were stored at −70°C until further use, and pro-
tein concentration was determined by the Bradford assay.
Western Blot Analysis
Equal amounts of protein extracts (30 μg/lane) were resolved by
SDS–polyacrylamide gel electrophoresis and transferred onto a nitro-
cellulose membrane (Sigma-Aldrich). The membrane was blocked in
Tris-buffered saline, containing 2% glycine and 3% nonfat dried
milk overnight at 4°C. The membrane was then incubated with spe-
cific antibodies to IκB-α, pIκB-α, p65, and actin for 2 hours at 37°C
followed by horseradish peroxidase–labeled secondary antibody for
1.5 hours at 37°C. The reaction was developed using a chemilumini-
scence detection system. Densitometric analysis was performed using
Scion Image software (Scion Corporation, NIH, Bethesda, MD).
Relative index (RI) was calculated as follows:
RI: OD treatment=OD control:
MTS Assay
Patient-derived leukemic cells were exposed to increased concentra-
tions of DOX (0-2 μM), VCR (0-10 μM), CAPE (0-100 μg/ml), or
MG-132 (0-4 μM) to assess their effect on cell proliferation using the
CellTiter 96-AQueous One Solution Cell Proliferation Assay (Promega
Corporation, Madison, WI) according to the manufacturer’s instruc-
tions. Briefly, 5 × 105 cells per well were cultured in RPMI-1640 sup-
plemented with 15% of FCS for 24 hours, added with 20 μl of CellTiter
96-Aqueous One Solution Reagent containing a tetrazolium com-
pound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H -tetrazolium (MTS), and an electron-coupling
reagent (phenazine ethosulfate). The plate was incubated at 37°C
for 2.5 hours in a humidified atmosphere with 5% CO2. Absorbance
at 492 nm corresponding to a reduction of MTS was measured using
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a microtiter plate reader (Multiscan EX; Thermo-Electron Corpora-
tion, Waltham, MA) [32].
Cell Cycle Analysis
The different cell cycle stages in the DOX-, VCR-, CAPE-, and
MG-132–treated groups were measured by flow cytometry. Cells (1 ×
106/ml) were harvested, washed once with ice-cold PBS, and fixed with
1 ml of ice-cold 70% ethanol at 4°C for 30 minutes. Next, PL104
cells were incubated with 1 μg/ml of 4′-6-diamidino-2-phenylindole
(DAPI; Roche S.A., Buenos Aires, Argentina)–0.1% Triton X-100 for
30minutes at roomtemperature [33], and cellularDNAcontentwasmea-
sured using a PASS III flow cytometer (Partec, Görlitz, Germany). Fifteen
thousand events were acquired for each sample. Results were analyzed
using Cylchred 1.0.2 software (Cardiff University, United Kingdom).
Apoptosis Detection
Morphological features associated with apoptosis were analyzed by
acridine orange and EtBr staining after treatment of PL104 (6, 15,
and 24 hours), PDL cells (24 hours) and PBMCs (24 hours) with
DOX (0-2 μM), VCR (0-5 μM), CAPE (0-100 μg/ml), or MG-132
(0-4 μM) [34]. Briefly, cell pellets were resuspended in dye mix
(100 μg/ml acridine orange plus 100 μg/ml EtBr in PBS) and visual-
ized by fluorescence microscopy (Carl Zeiss, Germany). A minimum
number of 200 cells were counted, and the number of cells with frag-
mented nuclei, enlarged cytoplasm, and condensed chromatin were de-
termined. The percentage of apoptotic cells was calculated as follows:
%Apoptotic cells ¼ ðnumber of cells with apoptotic nuclei=
total number of cells countedÞ100
%Apoptotic index ¼ ð%apoptotic treated cells −
%apoptotic control cellsÞ
Apoptosis was also determined by staining of exposed phospha-
tidylserine with Annexin V–FITC/propidium iodide (PI; Apoptosis
Detection Kit; BioVision, Inc, Mountain View, CA) assay. PL104
cells were treated with DOX (1.5 and 2 μM), VCR (1 and 5 μM),
CAPE (50 and 100 μg/ml), or MG-132 (2 and 4 μM) for 24 hours.
Single-cell suspensions were analyzed by FACScan (Becton Dickinson,
San Jose, CA) and data acquired using WinMDI 2.8 software (Scripps
Institute, La Jolla, CA). Apoptotic cells were scored as Annexin V+,
PI− and Annexin V+, PI+.
Statistical Analysis
All data are presented as the mean ± SD for a series of three inde-
pendent experiments. Statistical analyses were performed with Prism3
software (GraphPad, San Diego, CA) using one-way analysis of vari-
ance followed by Tukey’s post hoc comparison test. Group differences,
treated versus untreated, were considered statistically significant when
P < .05.
Results
The Established Cell Line, PL104, Features a Mature
B-cell Phenotype
The immunophenotypic profile assessed by flow cytometry was
performed on PL104 to determine cell origin and degree of cell dif-
ferentiation (Table W1). Most PL104 cells expressed CD19, CD20,
CD22, CD79a, CD38, HLA-DR, and CD45 antigens plus μ/λ im-
munoglobulins on their surface (FigureW1). Myelomonocytic lineage–
relatedmarkers, such asMPO,CD33, CD117,CD11b, CD13, CD14,
and CD15, were not expressed. CD34 and CD10 antigens, which
indicate the degree of differentiation and maturation, commonly ex-
pressed in progenitors and immature cells, were also negative. Besides,
an aberrant expression of the CD71 marker was determined, in co-
incidence with the fact that this is a common feature in tumor cell lines
of different origins with high proliferation activity. The immuno-
phenotyping studies provided evidence that PL104 cell line expresses
phenotypic characteristics of B mature monoclonal cells.
The cell line presents a modal number of 46 chromosomes, evaluated
in 50 cells. Karyotype analysis, performed in 20 metaphases, showed
that 30% presented a chromosome marker: der(13) t(12;13)(q13;
p11) confirmed by FISH analysis (data not shown). No other numerical
or structural chromosome alterations were detected, being the definite
karyotype: 46,XX,der(13)t(12;13)(q13;p11)[6]/46,XX[14].
Epstein-Barr Virus Is Detected in PL104 Cells
Because the established cell line had a B phenotype, and the original
sample was typified as atypical myeloid lineage, and considering that
EBV has the ability to transform B cells into immortalized lympho-
blastoid cell lines (LCLs), we decided to investigate the expression of
EBV-related antigens on the PL104 cell line.
EBERs in situ hybridization, the criterion standard technique to
assess virus presence, revealed a nuclear localization of the signal with
a characteristic labeling of the inner nuclear membrane and around
the nucleolus of nearly all lymphoid cells (Figure 1A). To assess viral
protein expression, different MoAbs were used. Anti-EBNA1 staining
displayed a perinuclear pattern, whereas anti-LMP2A showed cytoplas-
mic and membrane labeling (Figure 1, B and C). Viral antigens were
expressed in almost every lymphoid cell. Finally, by means of PCR
a 122-bp amplification fragment of EBV DNA sequence encoding
BamH1 W was detected (Figure 1D).
DOX and VCR Treatment Significantly Reduce PL104
Proliferation Rate
As DOX and VCR are two antineoplastic agents commonly included
in most leukemia and lymphoma induction protocols, we decided to
test whether treatment of PL104 cells resulted in a reduction of cell pro-
liferation as assessed by [3H]TdR incorporation. All doses tested ex-
hibited an antiproliferative effect after 24 hours with maximal values
of 50% and 90% of growth inhibition for VCR and DOX, respectively
(Figure 2, A and B). However, highest inhibitions were reached after
48 hours of treatment either with 1.5 μMDOX (99.45 ± 0.11% growth
inhibition, P < .001) or 10 μM VCR (88.10 ± 5.08% growth inhibi-
tion, P < .001). These results reveal that both agents were able to in-
terfere with PL104 proliferation rate through significant inhibition of
this process. In addition, DOX showed a comparatively better response
than VCR in the tested conditions.
CAPE and MG-132 Exert an Antiproliferative Effect on
PL104 Cells and Modulate NF-κB Expression
The antiproliferative effect of CAPE and MG-132 was investigated
on PL104 cell line. Figure 2, C and D, shows that PL104 prolifera-
tion was abrogated after 24 and 48 hours of exposure to CAPE and
MG-132 compared with DMSO control cultures. Maximal cell growth
inhibition was 99.29 ± 0.30% and 99.27 ± 0.19% (P < .001), for
100 μg/ml CAPE and 4 μM MG-132, respectively. Lowest doses of
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MG-132 (0.125 and 0.25 μM) induced only 9% of inhibition after
24 hours of treatment.
NF-κB is known to promote cell survival and proliferation of normal
B lymphoid cells as well as of many tumor-related malignancies where
it is constitutively activated [35]. Thus, assuming that, among other
effects, both CAPE and MG-132 can affect NF-κB signaling pathway,
we evaluated the cytoplasmic and nuclear expressions of p65 protein by
Western blot. Figure 3 shows that treatment of PL104 cells with both
CAPE (50 μg/ml) and MG-132 (2 μM) for 2 hours resulted in a sig-
nificant increase in the cytoplasmic level of p65 and a further decrease
in the nuclear expression level. In addition, we investigated the expres-
sion level of NF-κB inhibitory subunit IκB-α and its phosphorylated
form pIκB-α after treatment with CAPE and MG-132. We found that
both compounds upregulated IκB-α and downregulated pIκB-α ex-
pression (Figure 3). In contrast, DOX (1.5 μM) and VCR (1 μM)
did not modulate the expression level of either cytoplasmic or nuclear
p65. Doxorubicine treatment of PL104 cells was not able to modify
IκB-α and pIκB-α levels and VCR slightly increased IκB-α and de-
creased pIκB-α (Figure 3). Thus, results indicate that CAPE and
MG-132 have a strong antiproliferative effect because only 0.7% of
cells still proliferate after treatment and that both compounds upregu-
lated NF-κB inhibitor while decreasing nuclear NF-κB levels, suggest-
ing an overall inhibitory effect.
DOX, VCR, CAPE, and MG-132 Differentially Affect Cell
Cycle Progression of PL104 Cell Line
As both chemotherapeutic agents and CAPE and MG-132 dis-
played an antiproliferative effect on in vitro treatment of PL104 cells,
we further examined their effects on cell mitotic cycle and DNA con-
tent of cells stained with DAPI by flow cytometry analysis. Figure 4A
shows that 53% of PL104 cells were in G0/G1 phase, 35% in S phase,
and only 12% were in G2/M phase. Treatment with 1.5 and 2 μM
DOX caused an increase in the proportion of cells in G0/G1 (74%-
73%) and a substantial decrease in both cells in G2/M phase (3%-
5%) and S phase (23%-24%) (Figure 4A). Vincristine treatment failed
to modify the percentage of cells in G0/G1 at the concentrations tested,
whereas the G2/M population distribution was only altered at 5 μM
(9% increase). A reduction of the percentage of cells in S phase was
Figure 1. EBV is detected in PL104 cells. (A) EBERs in situ hybridization showing a nuclear localization of the signal in PL104 cells
(original magnification, ×400; scale bar, 30 μm). (B) Perinuclear pattern after EBNA1 antigen labeling (original magnification, ×400; scale
bar, 30 μm). (C) LMP-2A detection by immunohistochemistry showing a cytoplasmic and membrane labeling (original magnification,
×400; scale bar, 30 μm). Arrows indicate a positive cell. (D) Polymerase chain reaction amplification of EBV DNA sequence, BamH1
W. Lane 1: PL104 cells. Lane 2: A positive control of a known, positive cell line (EBV-positive LCL P3HR1). Lane 3: A negative control
distilled H2O replacing DNA. Lane 4: A 100-bp molecular weight size marker.
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observed at all doses tested (5%, 7%, and 6% for 0.5, 1, and 5 μM
VCR, respectively; Figure 4B). Assessment of cell cycle distribution
after 25 μg/ml CAPE showed no significant differences in the percent-
age of cells in each cell cycle phase compared with DMSO control. In
contrast, a higher percentage of cells in G0/G1 (67%) and a lower per-
centage of cells in G2/M phase (8.5%) were recorded after treatment
with 50 or 100 μg/ml CAPE. In addition, a substantial reduction of
cells in S phase was observed at 50 μg/ml CAPE (Figure 4C ). MG-
132 treatment increased the proportion of cells in G0/G1 phase and
decreased both the percentages of cells in G2/M and S phase (Fig-
ure 4D). Thus, PL104 distribution in the different phases of the cell
cycle varies with the compound used: DOX significantly retards G1→
S cell cycle transition, VCR mainly affects cells at S phase, CAPE
mainly affects cells at G0/G1, and MG-132 shows a partial effect on
all stages of cell cycle progression.
CAPE and MG-132 Treatments Show Greater Efficacy in
Apoptosis Induction Than DOX and VCR
Because treatment of PL104 cells with the above drugs resulted in
significant cell growth inhibition, we decided to evaluate whether this
biological effect caused cell death through apoptosis. Apoptosis hall-
marks were analyzed in PL104-treated cells after acridine orange and
EtBr staining. After 6 hours of treatment with increasing doses of
DOX, no significant cell death was observed (Figure 5A). A maximal
rate of 28.65 ± 2.68% of apoptosis (P < .001) was recorded after
24 hours. Treatment with VCR showed earlier apoptosis induction
beginning at 6 hours after 1-μM dose exposure (Figure 5A). The maxi-
mal apoptotic rate attained was of 47.34 ± 2.66% of apoptosis (P <
.001). CAPE and MG-132 showed a remarkable apoptosis induc-
tion in PL104 cells. Both treatments with 100 μg/ml CAPE and 2
to 4 μM MG-132 showed statistically significant apoptosis values in
6-hour exposure assays. Increased values were observed in a time/dose-
course–dependent manner, both with CAPE and MG-132. Maxi-
mal apoptotic rates were 77.10 ± 5.17% and 88.57 ± 6.09% (P <
.001) after CAPE (100 μg/ml) and MG-132 (4 μM) 24-hour expo-
sure, respectively (Figure 5A). The induction of apoptosis was further
confirmed by phosphatidylserine exposure on plasma membrane by
Annexin V–FITC/PI staining of PL104 cells and evaluated by flow
cytometry (Figure 5B). Results obtained for apoptotic rates were in
agreement with those obtained from morphological assessment. Over-
all, these results indicate that CAPE and MG-132 induced higher
apoptotic rates than DOX and VCR in PL104 cells, suggesting that
these compounds might affect critical aspects of death/survival balance
in this cell line having worth chemotherapeutic potential.
CAPE and MG-132 Are Potent Inducers of Apoptotic
Death on PDL Cells
To verify whether the effect of NF-κB inhibitors on PL104 cell
proliferation and apoptosis induction can be extended to different
leukemia cell types, similar studies were performed in bone marrow
samples obtained from patients with the characteristics described in
Materials and Methods. Doxorubicine and VCR were also tested as
control drugs. Figure 6A shows that treatment of PDL cells with
CAPE resulted in a remarkable inhibition of proliferation at all concen-
trations tested (0-100 μg/ml). The highest inhibition (69.80 ± 24.43%,
P < .001) was observed at 50 μg/ml CAPE. This value was consider-
ably higher than the maximal inhibitory effect observed with MG-132
treatment (25.17 ± 23.54%, P < .01) at 1 μM dose and also higher
than the percentages observed with DOX and VCR treatment.
Figure 2. DOX, VCR, CAPE, andMG-132 significantly reduced PL104
cell growth. Cell growth inhibition assessed by [3H]TdR incorporation
at 24 and 48 hours after exposure to different concentrations of DOX
(A), VCR (B), CAPE (C), and MG-132 (D). Results are expressed as
percentage of cell proliferation inhibition for each treatment (for ad-
ditional details, see Materials and Methods). Bars, mean ± SD of at
least three independent experiments (***P < .001).
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The percentage of apoptotic PDL cells after treatment with 100 μg/ml
CAPE was 42.04 ± 23.94% (P < .01) and 34.05 ± 26.30% (P < .01)
with 4 μM MG-132. In contrast, DOX and VCR treatment did not
induce significant apoptosis (Figure 6B). The percentage of apoptotic
cells was of 7.63 ± 7.43% with DOX treatment and 12.38 ± 9.79%
with VCR treatment. These results support a strong cytotoxic effect
for CAPE and MG-132 in PDL cells, most probably related to an
alteration of the cell survival/death balance, and confirm the pre-
dominance of cytostatic over cytotoxic effects of the conventional anti-
proliferative DOX and VCR compounds.
The Chemotherapeutic Agents, CAPE and MG-132, Have
No Considerable Cytotoxic Effect on Normal Mononuclear
Human Cells
The promising results obtained after treatment of PL104 cell line
and PDL cells with CAPE and MG-132 prompted us to evaluate
whether these compounds were able to exert a similar effect on normal
cells. In 24-hour morphological assays, only low rates of apoptosis
induction varying from 0.1% to 5% were observed in PBMC from
healthy donors either when exposed to CAPE and MG-132 or after
treatment with DOX and VCR (Figure 7A). However, the differences
in the apoptosis rate between drug-treated PL104 cells and drug-treated
normal PBMC showed statistically significant differences of 65.1%,
76.9%, 22.7%, and 32.9% (P < .001) for CAPE, MG-132, DOX,
and VCR, respectively (Figure 7B). When analyzing the differences in
the apoptosis rate between drug-treated PDL cells and normal PBMC,
smaller but still significant values were observed with CAPE (37.2%,
P < .001), MG-132 (29.5%, P < .01), and VCR (11.1%, P < .01; Fig-
ure 7B). These results suggest that selectivity toward malignant cells, in
cytotoxic effects, is considerably higher for CAPE and MG-132 than for
the conventional chemotherapeutic drugs DOX and VCR.
Simultaneous Exposure of PL104 Cells to DOX or VCR
and CAPE or MG-132 Results in an Increase of Apoptotic
Cell Death
To investigate whether CAPE or MG-132 can increase the sus-
ceptibility of PL104 cells to chemotherapeutic agents, we tested the
combined effect of DOX or VCR plus either CAPE or MG-132 at
concentrations associated with minimal lethality. Apoptotic rates were
evaluated in PL104 cells simultaneously exposed to the different com-
binations of drugs for 24 and 48 hours (Table 1). After a 24-hour ex-
posure, only VCR treatment combined with either CAPE or MG-132
showed a slight statistically significant increase in apoptosis percent-
age (8.6%, P < .05 and 11%, P < .001, respectively, vs the chemo-
therapeutic drug alone). However, after 48 hours, both DOX and
VCR treatment combined with either CAPE or MG-132 resulted in
a higher increase of 1.6- to 2-fold in apoptosis percentage (P < .001 vs
the chemotherapeutic drug alone), reaching in all cases a maximal
apoptotic rate of 54% to 57%. No significant effects were recorded
after CAPE and MG-132 combined treatment on PL104 cells. Col-
lectively, these findings indicate that the combination of chemothera-
peutic drugs with CAPE or MG-132 enhances the cytotoxic effect of
each drug alone.
Discussion
The experimental use of continuous human cell lines represents a
valuable tool for understanding the biology, pathogenesis, and treat-
ment options for various tumor malignancies. In this study, we report
the establishment of a novel cell line, PL104, from bone marrow as-
pirate of a patient with an atypical myeloid malignancy. PL104 cells
correspond to mature B monoclonal lymphocytes, EBV-positive. In
this type of cells, as well as in those infected by Kaposi sarcoma herpes-
virus (KSHV), activated NF-κB is considered a critical protective
mechanism against apoptotic stress [35].
Figure 3. CAPE and MG-132 treatment of PL104 cells modulate NF-κB expression. Nuclear or cytoplasmic protein extracts were sub-
jected to SDS-PAGE and Western blot analysis by using antibodies against p65, IκB-α, pIκB-α, and β-actin. (A) Representative results are
shown. Lane 1: RPMI-1640. Lane 2: DMSO 0.1% v/v 2 hours. Lane 3: CAPE 50 μg/ml 2 hours. Lane 4: MG-132 2 μM 2 hours. Lane 5:
DOX 1.5 μM 2 hours. Lane 6: VCR 1 μM 2 hours. (B) Bar graph showing the RI for each treatment. Upper bars, mean ± SD of at least
three independent experiments (*P < .05, **P < .01, ***P < .001).
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Figure 4. PL104 cell cycle distribution is affected after treatment with both chemotherapeutic agents, CAPE and MG-132. Cell cycle
analysis of PL104 cells exposed to a range of concentrations of DOX (A), VCR (B), CAPE (C), and MG-132 (D). The percentage of cells in
G0/G1, S, and G2/M phases is indicated in the bar graph (left of each panel). Upper bars, mean ± SD of at least three independent
experiments (*P < .05, **P < .01, ***P < .001). A representative DNA histogram of each treatment is shown on the right side of each
panel. Control cells were treated with RPMI-1640 medium or 0.1% v/v DMSO.
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The physiological functions of NF-κB and many upstream regu-
lators have been intensively studied, revealing an essential role for this
transcription factor in inflammation and lymphoid organ develop-
ment and as a positive mediator of T and B lymphocyte maturation,
activation, proliferation, and survival [36]. Its constitutive activity is
also crucial for cell survival, proliferation, and differentiation; thus,
its inhibition may facilitate apoptosis in different cell types [37,38].
Many NF-κB inhibitors have emerged over the recent years in an at-
tempt to contribute to cancer treatment, although only one (bortezomib)
is currently included in some chemotherapeutic protocols [39]. In
this work, we evaluated the relevance of CAPE and MG-132, which,
among their broad effects, can inhibit NF-κB, on PL104 cell line in
terms of cell survival and proliferation. Both agents had a strong anti-
proliferative effect on PL104 cells, which was dose- and time-dependent
Figure 5. CAPE and MG-132 are apoptosis inducers stronger than DOX and VCR on treatment of PL104 cells. Apoptosis induction after
treatment of PL104 cells with the four drugs. (A) Morphological evaluation of apoptosis of cells exposed to different concentrations of
DOX, VCR, CAPE, or MG-132 for 6, 15, and 24 hours. Results are expressed as the percentage of cells stained with acridine orange and
EtBr having morphological hallmarks of apoptosis. Bars, mean ± SD of at least three independent experiments (*P < .05, **P < .01,
***P < .001). Control cells were treated with RPMI-1640 or 0.1%v/v DMSO. (B) Evaluation of apoptosis through Annexin V–FITC/IP
staining and flow cytometry of PL104 cells exposed to different concentrations of DOX, VCR, CAPE, or MG-132 for 24 hours.
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and involved cell cycle deregulations. As suggested by Keller et al. [35]
on KSHV- and EBV-lymphoma cells, inhibition of NF-κB may be
related to the down-regulation of specific antiapoptototic and growth-
related proteins involved in controlling cell survival, thus leading to
a reduction of cell proliferation. In agreement with our results, the
NF-κB inhibitor Bay 11-7082 has also been reported to downregulate
a specific subset of genes and to induce apoptosis in IB4 cells, an EBV-
infected cord blood–derived LCL [40].
We showed that CAPE treatment increased the percentage of cells
in G0/G1 and decreased the percentage of cells in S and G2/M phase.
These modifications in PL104 cell cycle distribution are in agreement
with the ability of this compound to inhibit DNA, RNA, and protein
synthesis [41], thus delaying cell cycle progression to G2/M phase.
Cell cycle analysis of PL104 cells revealed that MG-132, similarly to
CAPE, reduced the percentage of cells at S and G2/M phases and in-
creased the percentage of G0/G1 cells. These findings may be related to
Figure 6. CAPE and MG-132 treatment showed an antiproliferative and cytotoxic effect on PDL cells. (A) PDL cells were cultured in the
presence of increasing concentrations of DOX, VCR, CAPE, or MG-132 for 24 hours. Results are presented as percentage of cell pro-
liferation inhibition of each treatment. (B) Apoptosis induction evaluated after acridine orange and EtBr staining. PDL cells were treated
for 24 hours with DOX, VCR, CAPE, or MG-132. Bars, mean ± SD of at least three independent experiments (ns indicates not significant,
*P < .05, **P < .01, ***P < .001).
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the fact that inhibition of the 26S proteasome function blocks cellular
transition from G1 to S phase and from late S to G2/M phase [42].
We further analyzed the antiproliferative activity of DOX and VCR,
two cytostatic drugs used to suppress cell growth and proliferation
of leukemia, lymphoma, and solid tumors cells. Both DOX and VCR
were able to significantly inhibit cell proliferation, although DOX-
treated cells were more sensitive to the antiproliferative effects than
VCR-treated cells at 1 μM (76.6% and 48.7% growth inhibition,
respectively). Cell cycle analysis by flow cytometry demonstrated that
DOX increased the percentage of cells at G0/G1 with a concomitant
reduction in the percentage of cells at S phase. Thus, the accumu-
lation of PL104 cells at G0/G1 retarded S phase entry. Vincristine-
treated PL104 cells showed a significantly reduced percentage of cells
at S phase, suggesting that VCR might be able to influence the G2-
to-M progression by retaining cells in a stage of the cell cycle where
they are less sensitive to the cytotoxic effects [43].
The therapeutic goal of cancer treatment is to induce apoptotic death
of cancer cells rather than necrosis due to the deleterious consequences
of the latter, which include leakage of lysosomal enzymes to the extra-
cellular media and spawning a substantial inflammatory reaction. CAPE
Figure 7. DOX, VCR, and NF-κB inhibitors have no considerable cytotoxic effect on normal PBMCs. Cells were treated with DOX, VCR,
CAPE, or MG-132 at different concentrations for 24 hours. (A) Acridine orange and EtBr staining was performed to determine the per-
centage of apoptotic cell death. Bars, mean ± SD of at least three independent experiments. (B) Apoptosis comparative analysis for
1.5 μM DOX, 5 μM VCR, 100 μg/ml CAPE, and 4 μM MG-132 treatments among different cell types: a, PDL cells; b, normal PBMCs; c,
PL104 cells (ns indicates not significant, *P < .05, **P < .01, ***P < .001).
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andMG-132maximal concentrations caused high levels of apoptotic cell
death of 77.1% and 88.6%, respectively, with no signs of significant
necrosis in PL104 cells, values considerably higher than the ones reached
with DOX and VCR, suggesting that these two agents mainly exert anti-
proliferative effects with little or no cytotoxic effect on PL104 cells.
It has been previously found that proteasome inhibitors may cause
cell death of tumor cell lines of different origins and preclinical studies
have demonstrated antineoplastic activity in hematological malignancies
and solid tumors [44,45]. CAPE has been reported to inhibit the
growth of oral carcinoma [46] and to produce a cytotoxic effect against
brain tumors [47], prostate and breast cancer cells [48,49], and human
myeloid leukemia cells [50].
Beyond antiproliferative and cytotoxic effects on PL104 cells, our
study showed that both CAPE and MG-132 exerted dissimilar effects
on PDL cells. CAPE showed higher antiproliferative potential than
MG-132. However, both drugs had a similar effect on apoptosis in-
duction in PDL cells as opposed to our findings with PL104 cells,
where MG-132 induced higher levels of apoptosis than CAPE.
The chemotherapeutic agents DOX and VCR displayed only anti-
proliferative activity, which was not associated to cell death, as
evidenced by our apoptosis studies. Although DOX and VCR are
known to have mainly an antiproliferative effect against tumor human
malignancies, our study demonstrated that the percentage of cell pro-
liferation inhibition reached with CAPE was 25% to 35% higher than
that with DOX and VCR. This finding is most valuable because, to
our knowledge, this is the first study to assess the effects of CAPE and
MG-132 on PDL cells.
Drug selectivity contributes to minimize or eliminate undesirable and
harmful side effects of cytotoxic drugs due to prolonged administra-
tion and is a crucial point when designing a suitable therapeutic proto-
col for patients with malignant neoplasias or when evaluating possible
new treatment agents. Thus, we analyzed the effect of CAPE and MG-
132, DOX and VCR on normal PBMCs. CAPE and MG-132 showed
enhanced selectivity of apoptosis toward PDL cells and PL104 cells
compared with normal PBMCs. These results are consistent with pre-
vious findings showing that, at concentrations inducing a high leuke-
mic cell apoptosis rate, proteasome inhibitors lactacystin and MG-132
only marginally induce apoptosis in human CD34+ hematopoietic
progenitor cells and moderately affect their outgrowth [45]. MG-132
cytotoxic selectivity may be because cancer cells have more defective
proteins accumulating at much higher rates than normal cells, thus in-
creasing their dependency on optimal proteasome function. The selec-
tivity of CAPE cytotoxic effects observed in our study has also been
shown in oral carcinoma cell lines compared with normal human oral
fibroblasts [46] and in medulloblastoma cells compared with human
fetal glial cells [51]. Although DOX and VCR treatment of normal
PBMCs had no considerable cytotoxic effect, both drugs also failed to
induce apoptosis in PDL cells.
Recent reports point out that safe and nontoxic cancer chemopre-
ventive phytochemicals can function as sensitizer drugs, increasing the
effectiveness of cancer treatment [47,52,53]. Similarly, inhibition of NF-
κB signaling could potentially be effective as a single agent or in com-
bination with radiotherapy or chemotherapy in pathologies that solely
depend on this transcription factor for survival [54,55]. Our results in
PL104 cell line demonstrate that subtoxic or sublethal concentrations
of DOX, VCR, CAPE, or MG-132 administered individually had little
effect on apoptosis induction, whereas combined treatment of cells with
CAPE or MG-132 plus a conventional chemotherapeutic drug resulted
in an enhancement of cell death. Drug combination/drug cocktails that
modulate apoptosis induction may be considered a powerful weapon
against different tumor malignancies and also a mean to enhance the
cytotoxic effect and reduce the toxicity of current anticancer agents.
In this work, CAPE and MG-132 showed a considerable potential as
apoptosis inductors on an LCL as well as on primary cells recovered
from patients with leukemia. Their cytotoxic effect was mainly restricted
to pathologic cells rather than normal ones, thus conferring a selective
action to both compounds and a promising treatment option that will
deserve further studies. Altering the thresholds of tumor cells to apop-
tosis induction and sensitizing them to establish therapy protocol is ex-
pected to contribute to progress in cancer therapy in the future.
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Table W1. Analysis of PL104 Cell Surface Antigens.
Result
CD2 Negative
CD3 Negative
CD4 Negative
CD5 Negative
CD7 Negative
CD8 Negative
CD10 Negative
CD11b Negative
CD13 Negative
CD14 Negative
CD15 Negative
CD16 Negative
CD19 Positive
CD20 Positive
CD22 Positive
CD33 Negative
CD34 Negative
CD38 Positive
CD41a Negative
CD45 Positive
CD56 Negative
CD64 Negative
CD71 Positive
CD79a Positive
CD117 Negative
MPO Negative
HLA DR Positive
λ chain Positive
κ chain Negative
Immunophenotypic profile of PL104 cells assessed by flow cytometry. A positive result was con-
sidered when the comparison of the staining pattern of a certain antibody (defined as a percentage)
was 20% over the corresponding percentage of the isotypic control.
Data in boldface emphasis correspond to P < .001.
Figure W1. PL104 cells correspond to mature B monoclonal lymphocytes. Dot pot graphics showing positive CD expression on PL104
assessed by flow cytometry.
